ELITE PHARMACEUTICALS INC /NV/ (ELTP)
D
Pipeline Grade
Financial Position (from SEC Filings)
$30.3M
Cash & Equivalents
$23.8M
Quarterly Burn Rate
$397M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-30 | Phase3 Readout | — |
| 2027-01-29 | Phase2 Readout | — |
| 2027-03-25 | Phase2 Readout | — |
| 2027-05-12 | Phase3 Readout | — |
Active Clinical Trials (12)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06869785 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | PHASE3 | Active Not Recruiting | 196 |
| NCT07136012 | OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardio... | PHASE3 | Recruiting | 11,000 |
| NCT07220759 | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | PHASE3 | Active Not Recruiting | 330 |
| NCT06559306 | Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder ... | PHASE3 | Recruiting | 752 |
| NCT07481630 | A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart... | PHASE3 | Recruiting | 400 |
| NCT06345339 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H... | PHASE3 | Recruiting | 2,800 |
| NCT06566820 | Continuation Protocol for Obstructive Sleep Apnea (OSA) | PHASE3 | Enrolling By Invitation | 1,280 |
| NCT06875973 | Pelacarsen Roll-over Extension Program | PHASE3 | Recruiting | 599 |
| NCT06865079 | 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femo... | PHASE2 | Active Not Recruiting | 270 |
| NCT05762107 | A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | PHASE2 | Recruiting | 186 |
| NCT06857955 | A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | PHASE2 | Active Not Recruiting | 399 |
| NCT07575932 | A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) | PHASE2 | Recruiting | 872 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.